Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30735089 | 1.00 | KDM4E (0.45) | KDM4EPKMGPR119TGFBR1KMT2A | |
| SCHEMBL30734613 | 0.85 | GPR119 (0.44) | KDM4EPKMGPR119KMT2A | |
| SCHEMBL26636386 | 0.85 | GPR119 (0.44) | KDM4EPKMGPR119KMT2A | |
| SCHEMBL30021366 | 0.83 | GPR119 (0.46) | KDM4EPKMGPR119KMT2A | |
| SCHEMBL20294497 | 0.83 | GPR119 (0.46) | KDM4EPKMGPR119KMT2A | |
| SCHEMBL26636754 | 0.80 | GPR119 (0.45) | KDM4EPKMGPR119TGFBR1FAAH | |
| SCHEMBL26619602 | 0.78 | SCN9A (0.49) | KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL30662958 | 0.78 | SCN9A (0.49) | KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL30735176 | 0.77 | GPR119 (0.50) | KDM4EPKMGPR119FAAH | |
| SCHEMBL30657348 | 0.77 | GPR119 (0.56) | KDM4EPKMGPR119TGFBR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | KDM4E 1040/4885PKM 4263/4885GPR119 2228/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | KDM4E 1040/4885PKM 4263/4885GPR119 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.